Read April's eNews
Growing Opportunities for our Network, featuring:
✅ Welcome from Tony Jones, CEO, One Nucleus
✅ Review of this year's BLSA (Building Life Science Adventures)
✅ Tony Jones reviews our Inaugural Annual Awards
✅ Boston Bootcamp Winners and What they Can Look Forward To
✅ BIO-Europe Spring - A review of Hot Topics and How to Maximise the Returns and Wellbeing
✅ Prepare for the BIO International Convention in San Diego
✅ Networking Event: Collaboration Opportunities in Puerto Rico for Life Sciences
Regulatory Compliant Tissue Microarrays
AMSBIO reports that its extensive range of FDA tissue microarrays reliably enhances tissue cross-reactivity (TCR) and other target validation studies.
These high-quality tissue microarrays (TMAs) enable high-throughput analysis of a panel of tissue types recognized by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Each TMA features multiple normal tissue types from 3 different donor samples on a single slide to enable simultaneous analysis and facilitate the identification of potential cross-reactive and…
Astex Pharmaceuticals Announce Key Data Presentations at the American Association For Cancer Research (AACR) 2024 Annual Meeting
Cambridge, UK, 3 April 2023 – Astex Pharmaceuticals, a pharmaceutical company based in Cambridge, UK, dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that it will make five key data presentations at AACR 2024 focusing on its Phase II-ready MDM2 antagonist, ASTX295. AACR 2024 will take place from April 5-10, 2024, at the San Diego Convention Center, San Diego,…
As technologies emerge that enable a wide range of naturally occurring medicinal compounds to be reproduced by a host plant within a controlled environment, is it time to review the use of plants as biofactories? Innovation facilitators Agri-TechE are partnering with the life-sciences network OneNucleus to explore the market potential of using plant factories to mass produce rare drugs. Find out more about the event here.
Contributing his expertise to the workshop is Malcolm Skingle, Director of Academic Liaison at GSK, who has seen the evolution of natural products over many…
Laverock Therapeutics announces appointment of Ali Elsley as Finance Director and expansion of team
Stevenage, UK, 26 March 2024 - Laverock Therapeutics, a gene-silencing company with a uniquely powerful technology for the development of programmable advanced therapies to tackle major diseases, today announces the appointment of Ali Elsley as Finance Director.
Ali has extensive experience in the biotechnology and pharma sector working with both private and public companies. She joins from Acacia Pharma Group plc, an early commercial-stage listed pharma company, where she was Group Financial…
• Leading precision medicine and nucleic acid therapy (NAT) innovators will harness their platforms to develop NAT drug candidates for novel gene targets with strong genetic association to sporadic ALS
• The programme will be supported by mechanism-based patient stratification biomarkers to identify likely responders and accelerate and derisk clinical development
OXFORD and HARWELL, UK – 26 March 2024 – The pioneering precision medicine company, PrecisionLife, and the MRC nucleic acid therapy research unit, NATA, today announce a collaboration to co-develop novel oligonucleotide therapies for…
Norwich Research Park showcased its latest collaborations with industry at its Enterprise Tuesday event held on Tuesday 5 March at the John Innes Conference Centre.
The event theme was ‘Problem solving through collaboration’ and featured a number of presentations by newly formed businesses that have emerged from research on the Park, a keynote speech from Innovate UK and a panel debate on ‘Preventative medicine, early intervention and healthy ageing’. The event was organised by Anglia Innovation Partnership, the science park management company at Norwich Research Park and was sponsored by…
Cancer Research Horizons, the innovation arm of Cancer Research UK, has announced the winners of its second Innovation & Entrepreneurship Awards.
In the field of oncology, the translation of innovative science faces numerous hurdles. These include securing initial funding amid increasing R&D costs and the necessity to gather specialised expertise to navigate scientific, entrepreneurial, financial and market challenges. The Innovation & Entrepreneurship Awards aim to celebrate researchers and innovators actively bridging the gap between oncology discoveries and positive patient…
Produced using a patented dry-spinning technology - CollaFibR™ from AMSBIO is a highly consistent collagen fibre matrix that closely mimics the biomechanical and biochemical properties of natural collagen scaffolds, offering a highly accurate representation of in-vivo conditions.
These innovative collagen fibres are seamlessly produced on a commercial scale using an automated state-of-the-art Good Manufacturing Process, catering to a variety of applications in 3D cell culture and tissue engineering.
Offered as a user friendly 12-well plate insert - CollaFibR™ scaffolds are perfect for…
FemTech and Women’s Health start-ups urged to join Discovery Park’s growth programme, offering a support package worth over £50K
The Special Edition of the ‘Discovery Spark’ growth programme was announced at Kent & Medway Women’s Health Innovation Summit
Sandwich, Kent, UK / 12th March 2024 / Discovery Park, Kent’s thriving life science community, has launched a special edition of their growth and support programme, Discovery Spark, for start-ups in FemTech and Women’s Health.
The programme was unveiled at Kent & Medway Women’s Health Innovation Summit, which brought together…